Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice

by John Talbot
     
 

View All Available Formats & Editions

Written with practitioners in mind, this new edition of Stephen’s Detection of Adverse Drug Reactions: Principle and Practice continues to be one of the corner stones of the pharmaceutical medicine list. The classic text covers the issues and problems involved in the detection of adverse drug reactions (ADRs) throughout the life cycle of

…  See more details below

Overview

Written with practitioners in mind, this new edition of Stephen’s Detection of Adverse Drug Reactions: Principle and Practice continues to be one of the corner stones of the pharmaceutical medicine list. The classic text covers the issues and problems involved in the detection of adverse drug reactions (ADRs) throughout the life cycle of a medicine from animal studies through to clinical trials, its introduction to the market, followed by wide clinical use, and eventual decline in use or withdrawal. The sixth edition is completely revised and updated including five new chapters on pharmacogenomics, ADRs with herbal medicines, safety of medical devices, safety issues with oncology drugs, and economic aspects of ADRs. All tables and web information needed in order to practice are included to make this sixth edition a complete primer for the new practitioner and a reference for the more experienced.

Editorial Reviews

From the Publisher
“A vast array of experts in the science of pharmacovigilance contribute to this book, but the editors have maintained a clarity of presentation, keeping in mind that communication is a key factor in pharmacovigilance.”  (Doody’s, 27 July 2012)

Doody's Review Service
Reviewer: Thomas L. Pazdernik, PhD (University of Kansas Medical Center)
Description: This is an updated and expanded authoritative resource on drug safety valuable to all who work in pharmacovigilance.
Purpose: The book was initiated by Myles Stephens, a giant in the field of pharmacovigilance communications. He has selected John Talbot and Jeff Aronson to carry on the expansion and updating of this classic reference on drug safety. They have done a marvelous job with this sixth edition.
Audience: This is an excellent reference source for anyone who works in pharmacovigilance or has an interest in adverse drug reactions, including regulatory authorities, pharmaceutical companies, and academicians.
Features: It reviews all aspects of adverse drug reactions throughout the life cycle of a medicinal agent. The focus is on both basic toxicology and clinical trials, keeping in mind the importance of communication of information related to pharmacovigilance, risk management, and legal and regulatory requirements. The safety of biotherapeutics and vaccines are also covered in this edition. Moreover, new chapters have been added on pharmacogenetics, proactive risk management, societal considerations, and the safety of drugs used in oncology and herbal medicines. Appendix 1 provides websites relevant to pharmacovigilance along with an analysis of their contents and Appendix 2 provides guidelines and a checklist for reporting adverse drug reactions anecdotally in journals. The book is well written and extensively referenced.
Assessment: This remains a classic authoritative resource for anyone working in the area of pharmacovigilance. Moreover, it brings to this topic advances in toxicological sciences as well as in the handling of bioinformation. A vast array of experts in the science of pharmacovigilance contribute to this book, but the editors have maintained a clarity of presentation, keeping in mind that communication is a key factor in pharmacovigilance.

Read More

Product Details

ISBN-13:
9780470986349
Publisher:
Wiley
Publication date:
12/19/2011
Edition description:
New Edition
Pages:
750
Product dimensions:
6.80(w) x 9.80(h) x 1.80(d)

What People are saying about this

From the Publisher
“A vast array of experts in the science of pharmacovigilance contribute to this book, but the editors have maintained a clarity of presentation, keeping in mind that communication is a key factor in pharmacovigilance.” (Doody’s, 27 July 2012)

Meet the Author

John Talbot, Senior Lecturer, University of Hertfordshire, UK. Formerly Director, Global Drug Safety, AstraZeneca R&D Charnwood, Loughborough, Leicestershire, UK

Jeffrey Aronson, Reader in Clinical Pharmacology, University of Oxford, Oxford, UK and President Emeritus of the British Pharmacological Society

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >